Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

"The completion of our critical study for LAVERDIA®-CA1 marks a major milestone in bringing forward an innovative therapy for canine lymphoma", said Dylan Balsz, CEO of Anivive. "We are excited ...

Clinical trial sites across nine states have closed for one of the largest canine lymphoma studies Effectiveness data will soon be finalized for statistical review and FDA submission LONG BEACH ...

Feb. 14, 2025 /PRNewswire/ -- Anivive, a software-driven pet health company, today announced the successful completion of its pivotal field study evaluating the safety and effectiveness of ...

Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...

The biggest stories of the day delivered to your inbox.

Most major sections of the new animal drug application for Laverdia-CA1 have been deemed complete by the FDA, bringing the drug closer to approval The field study for Laverdia-CA1’s (verdinexor ...